Prashant Yadav
@prof-yadav.bsky.social
Better health & economic development through better supply chains, globally. #globalhealth #supplychain #pharmaceuticals #vaccine #access
Economics
40%
Business
30%
Pinned
Prashant Yadav
@prof-yadav.bsky.social
· Nov 24
Welcome to BSky!
I’m a healthcare supply chain and delivery systems academic-practitioner. I share research + musings on supply chains (manufacturing, procurement, distribution, financing) for health technologies (Rx, Vx, Dx) and pandemic medical countermeasures. Follow me for more on these topics!
I’m a healthcare supply chain and delivery systems academic-practitioner. I share research + musings on supply chains (manufacturing, procurement, distribution, financing) for health technologies (Rx, Vx, Dx) and pandemic medical countermeasures. Follow me for more on these topics!
Global Health Checkup: Deadly cough syrup brings reckoning for India pharma oversight
A fifth of the world's generic drugs and over half of all vaccines are made in India, where children have died after taking toxic cough syrup. Here's what's being done about it. Plus: biodiversity los...
www.healthbeat.org
👇read some of my thoughts re pharma manufacturing quality enforcement reform in India. @healthbeat.org by William Herkewitz
@cfr.org
#India #pharma #quality #enforcement #improvement
www.healthbeat.org/2025/10/23/g...
@cfr.org
#India #pharma #quality #enforcement #improvement
www.healthbeat.org/2025/10/23/g...
With 43 million deaths/ y (73% in LMICs) due to #NCDs, we need operational implementation, not just declarations. Pragmatic delivery systems to supply medicines, and smarter demand forecasting are 2 simple ones to start with. My short article after the UNGA-HLM on NCDs. jointly with Aly Martinez.
Reposted by Prashant Yadav
Foreign Affairs
@foreignaffairs.com
· Aug 11
America’s Pill Problem
Tariffs won’t fix the country’s reliance on foreign medicines.
www.foreignaffairs.com
Thomas Bollyky, Chloe Searchinger, and @prof-yadav.bsky.social discuss the United States’ growing dependence on foreign sources for critical medicines—and call on policymakers to diversify the U.S. pharmaceutical supply chain:
Since 2020, I have frequently joined Tommy Tucker and WWL Radio's morning show to discuss pharmaceutical supply issues for their listeners in New Orleans and across the Gulf Coast. This morning, we talked about the Trump Administration’s pharmaceutical tariffs
@cfr.org
audacy.com/podcast/wwl-...
@cfr.org
audacy.com/podcast/wwl-...
Reposted by Prashant Yadav
Foreign Affairs
@foreignaffairs.com
· Aug 5
America’s Pill Problem
Tariffs won’t fix the country’s reliance on foreign medicines.
www.foreignaffairs.com
The United States’ growing dependence on foreign drugs puts national security at risk—but imposing high tariffs on essential generic medicines will not make the country safer, argue @prof-yadav.bsky.social, Chloe Searchinger, and Thomas Bollyky.
Reposted by Prashant Yadav
Foreign Affairs
@foreignaffairs.com
· Jul 22
America’s Pill Problem
Tariffs won’t fix the country’s reliance on foreign medicines.
www.foreignaffairs.com
The United States’ growing dependence on foreign drugs puts national security at risk—but imposing high tariffs on essential generic medicines will not make the country safer, argue @prof-yadav.bsky.social and Thomas Bollyky.
Prashant Yadav
@prof-yadav.bsky.social
· Jul 13
Procuring #pandemic #countermeasures needs new skills, smarter contracts & higher risk tolerance. Demand is highly volatile, suppliers may be new, production incentives are weak, & often need #procurement before reg approval. Key themes I shared at the recent ADB symposium on pandemics.
@cfr.org
@cfr.org
On 11 July 2025, the Asian Development Bank will host a Symposium on Multilateral Financing for Pandemic Preparedness and Response in Manila. The symposium features a session on procurement for medical countermeasures. You can also join us via Zoom: lnkd.in/ei7zKtX6.
Prashant Yadav
@prof-yadav.bsky.social
· Jun 22
The US needs to address the lack of supply resilience for critical generic medicines. But it needs other tools of industrial policy (hint: not tariffs). @jaredshopkins.bsky.social @wsj.com
www.wsj.com/health/pharm...
Thanks for including my thoughts.
#generic #pharma #supplychain #resilience
www.wsj.com/health/pharm...
Thanks for including my thoughts.
#generic #pharma #supplychain #resilience
Prashant Yadav
@prof-yadav.bsky.social
· May 27
Amid #WHA78, the WHS session on “Taking Responsibility for Health in a Fragmented World” sparked some key reflections for me. Grateful to @Ilona Kickbusch for thoughtful questions on trade, industrial policy, & global health. Hope it sparks a continued dialogue. 👇images copyright World Health Summit
Prashant Yadav
@prof-yadav.bsky.social
· May 20
If you are in Geneva at #WHA78 join us for this
@worldhealthsummit.bsky.social #WHS side event "Taking Responsibility for Health in a Fragmenting World."
📍 InterContinental Hotel - Ballroom A
🗓️ May 21, 2025 | 17:00 CEST
👉 Full program here: lnkd.in/dUbBEV8W
@cfr.org
@worldhealthsummit.bsky.social #WHS side event "Taking Responsibility for Health in a Fragmenting World."
📍 InterContinental Hotel - Ballroom A
🗓️ May 21, 2025 | 17:00 CEST
👉 Full program here: lnkd.in/dUbBEV8W
@cfr.org
Reposted by Prashant Yadav
Executive Order to Lower U.S. Drug Prices Could Hurt the Poorest Countries | Think Global Health
Cascading adoption of most-favored-nation drug pricing could erode affordable access to essential medicines
www.thinkglobalhealth.org
CFR Senior Fellow @prof-yadav.bsky.social analyzes how the White House's executive order to lower drug prices by invoking a most-favored-nation clause could have cascading effects on medicine access in low-income countries.
Reposted by Prashant Yadav
Nsikan Akpan
@monscience.bsky.social
· May 16
Executive Order to Lower U.S. Drug Prices Could Hurt the Poorest Countries | Think Global Health
Cascading adoption of most-favored-nation drug pricing could erode affordable access to essential medicines
www.thinkglobalhealth.org
The U.S. executive order on most-favored-nation drug pricing could have cascading implications for global health agencies serving LMICs. It could undermine mechanisms that enable affordable access to essential medicines. - @prof-yadav.bsky.social
Prashant Yadav
@prof-yadav.bsky.social
· May 16
The new US Exec Order on pharma MFN pricing sticks to high-income countries (thankfully). But it risks reigniting broader MFN demands by MICs, jeopardizing low-tier prices critical for access in low-income countries. I unpack this in my latest ThinkGlobalHealth @cfr.org piece. (Link in next post) 👇
Prashant Yadav
@prof-yadav.bsky.social
· May 12
cgdev.org
Some other discussion points re tiered pricing, comparing company-led tiered pricing vs more systematically established bands (not directly related to the MFN clause) that we have deliberated in the past.
cgdev.org/sites/defaul...
cgdev.org/sites/defaul...
Prashant Yadav
@prof-yadav.bsky.social
· May 12
In 👇 we argue that each country would pay a price pharmaceuticals that is commensurate with the value it provides to that country's health system.
pubmed.ncbi.nlm.nih.gov/32185365/
pubmed.ncbi.nlm.nih.gov/32185365/
Prashant Yadav
@prof-yadav.bsky.social
· May 12
assets.publishing.service.gov.uk
👇 link to a 2010 study conducted for the Industry Government Forum on Access to Medicines to review current literature on differential pricing, under what conditions does it improve overall welfare, and some operational/practical considerations.
assets.publishing.service.gov.uk/media/5a78b6...
assets.publishing.service.gov.uk/media/5a78b6...
Prashant Yadav
@prof-yadav.bsky.social
· May 12
Creating a single price for pharmaceuticals (through MFN) is both inefficient and inequitable. There is sufficient and strong evidence for this. Also, an MFN clause hurts the poorest countries the most.
Links to my review studies and past work on this are in the following posts.
Links to my review studies and past work on this are in the following posts.
The i3 program for African health startups is back for Phase 2! After backing 60 early-stage startups in Phase 1, we’re now supporting 7 growth-stage companies using innovative tech to improve pharmacy access for patients. 7 outstanding companies and founders ... #Africa #healthtech #i3 #pharmacy
Prashant Yadav
@prof-yadav.bsky.social
· Apr 27
Rwanda is emerging as a leading example of building world-class digitalization+ tech into the health system. Driven by strong govt commitment & health sector leadership; national ID & insurance systems; expanded broadband access at clinics; and the support of nimble, responsive, and trusted partners
Prashant Yadav
@prof-yadav.bsky.social
· Apr 25
Since 2020, I’ve been grateful to WWL Radio (which covers across New Orleans and the Gulf Coast) for having me on their morning show to discuss pharmaceutical supply issues. ~Last week, we covered questions around potential #pharmaceutical #tariffs.
audacy.com/podcast/wwl-...
audacy.com/podcast/wwl-...
Prashant Yadav
@prof-yadav.bsky.social
· Apr 25
Honored to be on the Scientific Advisory Board of the #WorldVaccineCongress, which brings together top vaccine experts. Thanks to the panelists + engaged audience at this session on vaccine thermostability, from upstream tech to last-mile delivery. #vaccine #thermostability #supplychain
Prashant Yadav
@prof-yadav.bsky.social
· Apr 15
Uncertainty in trade policy is undermining the imp. goal of pharma supply chain diversification and reducing geographic concentration. Policy unpredictability is stalling these critical decisions. Article by @hannahkuchler.bsky.social
& colleagues @financialtimes.com (link next)
@cfr.org
& colleagues @financialtimes.com (link next)
@cfr.org
Prashant Yadav
@prof-yadav.bsky.social
· Apr 15
Millions in the U.S. take this drug. Tariffs might complicate their care.
Heparin is cheap and essential to millions of hospitalized people. Tariffs could disrupt the supply chain that gets ingredients from China to their beds.
washingtonpost.com
The U.S. (and the world) must diversify its heparin API supply. Currently, most comes from China. We need to diversify geographically & production processes. @sabrinamalhi.bsky.social @washingtonpost.com covers the tariff risks—grateful to share my thoughts.
washingtonpost.com/health/2025/...
washingtonpost.com/health/2025/...
Prashant Yadav
@prof-yadav.bsky.social
· Apr 15
Since 2020, I have frequently joined Tommy Tucker and WWL Radio in New Orleans + the Gulf Coast on their morning show WWL First News to talk about pharmaceutical supply issues. This morning, we discussed questions surrounding potential pharmaceutical tariffs.
@cfr.org
audacy.com/podcast/wwl-...
@cfr.org
audacy.com/podcast/wwl-...
Reposted by Prashant Yadav
U.S. Retreat from Gavi Cedes Influence to China's Vaccine Suppliers | Think Global Health
The loss of U.S. funding could leave Gavi with three options to downsize its operations
www.thinkglobalhealth.org
The Donald Trump administration reportedly plans to terminate U.S. funding to Gavi
@cfr.org Senior Fellow @prof-yadav.bsky.social and Chloe Searchinger outline how defunding the global vaccine initiative could open the door for China to grow its influence among strategic partners.
@cfr.org Senior Fellow @prof-yadav.bsky.social and Chloe Searchinger outline how defunding the global vaccine initiative could open the door for China to grow its influence among strategic partners.
Prashant Yadav
@prof-yadav.bsky.social
· Mar 28
Some pharma companies & distributors are stocking up the channel before the (potential) upcoming pharma tariffs take effect. The resulting "bullwhip effect" from this stockpiling will likely become more evident in the second half of 2025. @reuters.com @cfr.org
www.reuters.com/business/hea...
www.reuters.com/business/hea...